next generation glp 1 drugs The of GLP-1 weight loss GLP-1 Weight Loss Drugs Coming

In the UK, the MHRA controls drug regulations

Abbreviations Akt: Protein kinase B BMI: Body mass index cAMP: Cyclic adenosine monophosphate CGRP: Calcitonin gene-related peptide DM: Diabetes mellitus DPP: 4-dipeptidyl peptidase-4 GLP: 1-glucagon-like peptide-1 GLP: 1R-glucagon-like peptide-1 receptor HbA1c: Glycated hemoglobin IGF: Insulin-like growth factor MAPK: Mitogen-activated protein kinase mTOR: Mammalian target of rapamycin NF: B-nuclear factor B PI3K: Phosphoinositide 3-kinase PKA: cAMP-dependent protein kinase SGLT: 2-sodium-glucosecotransporter-2 T2DM: Type 2 diabetes mellitus References Iijima, T., Shibuya, M., Ito, Y., & Terauchi, Y

GLP-1 receptors have been identified in testicular tissue specifically on Leydig cells, which are the primary producers of testosterone

At 12 months, the weight change for those who discontinued treatment was -2.2%, compared with a -10.9% change for persistent patients

Some patients may notice faster early weight loss with this type of medication compared with GLP-1 options, which can make it appealing when someone wants a quicker initial response